Eli Lilly and Company announced on Monday detailed results from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating ...

The jab has already been hailed a breakthrough in the war on obesity. Now, US researchers have found those on the injections ...

Novo Nordisk's competitive position is strengthening, driven by strong sales growth in Wegovy, Ozempic, and rare diseases.